Business
Cardio Diagnostics Publishes Research Highlighting the Reversibility of Epigenetic Signatures of Coronary Heart Disease
The study represents a significant breakthrough in understanding the potential for reversing and measuring epigenetic changes associated with coronary heart
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":"\nThe study represents a significant breakthrough in understanding the potential for reversing and measuring epigenetic changes associated with coronary heart disease after therapeutic intervention\n\n\n CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced the publication of groundbreaking research in the journal Genes. The study titled \"The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation\" sheds light on the potential of reversing epigenetic changes associated with coronary heart disease (CHD) through smoking cessation.\n\n\nCoronary heart disease, a leading cause of death worldwide, has long been linked to smoking. However, until now, the possibility of reversing its adverse effects at the epigenetic level through smoking cessation has remained unexplored. This new study represents a breakthrough in understanding the potential for reversing epigenetic changes associated with coronary heart disease.\n\n\nThe study examined the impact of smoking cessation on the six DNA methylation sites assessed by Cardio Diagnostics’ PrecisionCHD test. Data from 39 research participants who enrolled in a 90-day program of monitored smoking cessation were leveraged. PrecisionCHD, an AI-driven integrated epigenetic-genetic test for diagnosing CHD, utilizes a machine learning model to interpret the signals of six methylation-sensitive digital PCR (MSdPCR) assays and ten single nucleotide polymorphisms (SNPs) to determine CHD status. This novel approach offers two significant advantages. Firstly, it provides personalized insights into potentially modifiable lifestyle or physiological factors. Secondly, as DNA methylation is dynamic, the test serves as a mechanism to evaluate the success and efficacy of CHD therapy, enabling real-time monitoring of therapeutic interventions.\n\n\nRobert Philibert, M.D., Ph.D., Chief Medical Officer of Cardio Diagnostics and the study's lead author, explained the study’s methodology and significance: “We meticulously examined a cohort of individuals who quit smoking. Using proprietary methylation sensitive digital PCR techniques, we observed an interesting phenomenon—the epigenetic signatures associated with CHD began to revert after only three month...